Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients

Chihiro Makimura, Tokuzo Arao, Hiromichi Matsuoka, Masayuki Takeda, Hidemi Kiyota, Junji Tsurutani, Yoshihiko Fujita, Kazuko Matsumoto, Hideharu Kimura, Masatomo Otsuka, Atsuko Koyama, Chiyo Imamura, Takeharu Yamanaka, Kyoko Tanaka, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cytokine signaling is involved in pain and opioid-receptor signaling. In this prospective study, we studied the plasma cytokine levels in order to identify candidate biomarkers for predicting resistance to morphine treatment in a cohort of opioid-treatment-naïve cancer patients. We analyzed pain rating and the plasma concentrations of 26 cytokines at baseline and after morphine treatment using a multiplex immunoassay system for the following cytokines: eotaxin, colony stimulating factor, granulocyte (G-CSF), colony stimulating factor granulocyte-macrophage (GM-CSF), interferon α2 (IFN-α2), IFN-α, interleukin 1α (IL-1α), IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein la (MIP-1α), MIP-1β, tumor necrosis factor-α (TNF-α) and TNF-β. No correlation was observed between the clinical characteristics and the numerical rating scale for pain at baseline or among patients who developed resistance to morphine treatment. Interestingly, the plasma concentration of MIP-1α significantly decreased during morphine treatment (day 8 vs. baseline, p=0.03). Regarding the baseline plasma cytokine concentrations, none of the cytokine levels were correlated with the numerical rating scale for pain at baseline; however, the baseline plasma concentrations of eotaxin, IL-8, IL-12 (p40), IL-12 (p70), MIP-1α and MIP-1β were significantly lower in patients who required a high dose of morphine or who developed resistance to morphine treatment. In conclusion, this is the first report revealing that the plasma concentrations of several cytokines were significantly modulated during treatment and were correlated with treatment outcome of morphine. Our results suggest that plasma cytokine levels may be promising biomarkers for morphine treatment and that they warrant further study.

Original languageEnglish
Pages (from-to)4561-4568
Number of pages8
JournalAnticancer Research
Volume31
Issue number12
Publication statusPublished - 2011 Dec

Fingerprint

Morphine
Prospective Studies
Cytokines
Interleukin-12
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor
Therapeutics
Interleukin-8
Interleukin-1
Pain
Tumor Necrosis Factor-alpha
Biomarkers
Macrophage Inflammatory Proteins
Interleukin-15
Interleukin-7
Nociceptors
Interleukin-13
Interleukin-17
Chemokine CCL2

Keywords

  • Cytokines
  • IL-12
  • MIP-1α
  • Morphine
  • Plasma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Makimura, C., Arao, T., Matsuoka, H., Takeda, M., Kiyota, H., Tsurutani, J., ... Nakagawa, K. (2011). Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. Anticancer Research, 31(12), 4561-4568.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. / Makimura, Chihiro; Arao, Tokuzo; Matsuoka, Hiromichi; Takeda, Masayuki; Kiyota, Hidemi; Tsurutani, Junji; Fujita, Yoshihiko; Matsumoto, Kazuko; Kimura, Hideharu; Otsuka, Masatomo; Koyama, Atsuko; Imamura, Chiyo; Yamanaka, Takeharu; Tanaka, Kyoko; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Anticancer Research, Vol. 31, No. 12, 12.2011, p. 4561-4568.

Research output: Contribution to journalArticle

Makimura, C, Arao, T, Matsuoka, H, Takeda, M, Kiyota, H, Tsurutani, J, Fujita, Y, Matsumoto, K, Kimura, H, Otsuka, M, Koyama, A, Imamura, C, Yamanaka, T, Tanaka, K, Nishio, K & Nakagawa, K 2011, 'Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients', Anticancer Research, vol. 31, no. 12, pp. 4561-4568.
Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J et al. Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. Anticancer Research. 2011 Dec;31(12):4561-4568.
Makimura, Chihiro ; Arao, Tokuzo ; Matsuoka, Hiromichi ; Takeda, Masayuki ; Kiyota, Hidemi ; Tsurutani, Junji ; Fujita, Yoshihiko ; Matsumoto, Kazuko ; Kimura, Hideharu ; Otsuka, Masatomo ; Koyama, Atsuko ; Imamura, Chiyo ; Yamanaka, Takeharu ; Tanaka, Kyoko ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients. In: Anticancer Research. 2011 ; Vol. 31, No. 12. pp. 4561-4568.
@article{1b3bd044c3e34c93847acab5b6556d7e,
title = "Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients",
abstract = "Cytokine signaling is involved in pain and opioid-receptor signaling. In this prospective study, we studied the plasma cytokine levels in order to identify candidate biomarkers for predicting resistance to morphine treatment in a cohort of opioid-treatment-na{\"i}ve cancer patients. We analyzed pain rating and the plasma concentrations of 26 cytokines at baseline and after morphine treatment using a multiplex immunoassay system for the following cytokines: eotaxin, colony stimulating factor, granulocyte (G-CSF), colony stimulating factor granulocyte-macrophage (GM-CSF), interferon α2 (IFN-α2), IFN-α, interleukin 1α (IL-1α), IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein la (MIP-1α), MIP-1β, tumor necrosis factor-α (TNF-α) and TNF-β. No correlation was observed between the clinical characteristics and the numerical rating scale for pain at baseline or among patients who developed resistance to morphine treatment. Interestingly, the plasma concentration of MIP-1α significantly decreased during morphine treatment (day 8 vs. baseline, p=0.03). Regarding the baseline plasma cytokine concentrations, none of the cytokine levels were correlated with the numerical rating scale for pain at baseline; however, the baseline plasma concentrations of eotaxin, IL-8, IL-12 (p40), IL-12 (p70), MIP-1α and MIP-1β were significantly lower in patients who required a high dose of morphine or who developed resistance to morphine treatment. In conclusion, this is the first report revealing that the plasma concentrations of several cytokines were significantly modulated during treatment and were correlated with treatment outcome of morphine. Our results suggest that plasma cytokine levels may be promising biomarkers for morphine treatment and that they warrant further study.",
keywords = "Cytokines, IL-12, MIP-1α, Morphine, Plasma",
author = "Chihiro Makimura and Tokuzo Arao and Hiromichi Matsuoka and Masayuki Takeda and Hidemi Kiyota and Junji Tsurutani and Yoshihiko Fujita and Kazuko Matsumoto and Hideharu Kimura and Masatomo Otsuka and Atsuko Koyama and Chiyo Imamura and Takeharu Yamanaka and Kyoko Tanaka and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2011",
month = "12",
language = "English",
volume = "31",
pages = "4561--4568",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients

AU - Makimura, Chihiro

AU - Arao, Tokuzo

AU - Matsuoka, Hiromichi

AU - Takeda, Masayuki

AU - Kiyota, Hidemi

AU - Tsurutani, Junji

AU - Fujita, Yoshihiko

AU - Matsumoto, Kazuko

AU - Kimura, Hideharu

AU - Otsuka, Masatomo

AU - Koyama, Atsuko

AU - Imamura, Chiyo

AU - Yamanaka, Takeharu

AU - Tanaka, Kyoko

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2011/12

Y1 - 2011/12

N2 - Cytokine signaling is involved in pain and opioid-receptor signaling. In this prospective study, we studied the plasma cytokine levels in order to identify candidate biomarkers for predicting resistance to morphine treatment in a cohort of opioid-treatment-naïve cancer patients. We analyzed pain rating and the plasma concentrations of 26 cytokines at baseline and after morphine treatment using a multiplex immunoassay system for the following cytokines: eotaxin, colony stimulating factor, granulocyte (G-CSF), colony stimulating factor granulocyte-macrophage (GM-CSF), interferon α2 (IFN-α2), IFN-α, interleukin 1α (IL-1α), IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein la (MIP-1α), MIP-1β, tumor necrosis factor-α (TNF-α) and TNF-β. No correlation was observed between the clinical characteristics and the numerical rating scale for pain at baseline or among patients who developed resistance to morphine treatment. Interestingly, the plasma concentration of MIP-1α significantly decreased during morphine treatment (day 8 vs. baseline, p=0.03). Regarding the baseline plasma cytokine concentrations, none of the cytokine levels were correlated with the numerical rating scale for pain at baseline; however, the baseline plasma concentrations of eotaxin, IL-8, IL-12 (p40), IL-12 (p70), MIP-1α and MIP-1β were significantly lower in patients who required a high dose of morphine or who developed resistance to morphine treatment. In conclusion, this is the first report revealing that the plasma concentrations of several cytokines were significantly modulated during treatment and were correlated with treatment outcome of morphine. Our results suggest that plasma cytokine levels may be promising biomarkers for morphine treatment and that they warrant further study.

AB - Cytokine signaling is involved in pain and opioid-receptor signaling. In this prospective study, we studied the plasma cytokine levels in order to identify candidate biomarkers for predicting resistance to morphine treatment in a cohort of opioid-treatment-naïve cancer patients. We analyzed pain rating and the plasma concentrations of 26 cytokines at baseline and after morphine treatment using a multiplex immunoassay system for the following cytokines: eotaxin, colony stimulating factor, granulocyte (G-CSF), colony stimulating factor granulocyte-macrophage (GM-CSF), interferon α2 (IFN-α2), IFN-α, interleukin 1α (IL-1α), IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein la (MIP-1α), MIP-1β, tumor necrosis factor-α (TNF-α) and TNF-β. No correlation was observed between the clinical characteristics and the numerical rating scale for pain at baseline or among patients who developed resistance to morphine treatment. Interestingly, the plasma concentration of MIP-1α significantly decreased during morphine treatment (day 8 vs. baseline, p=0.03). Regarding the baseline plasma cytokine concentrations, none of the cytokine levels were correlated with the numerical rating scale for pain at baseline; however, the baseline plasma concentrations of eotaxin, IL-8, IL-12 (p40), IL-12 (p70), MIP-1α and MIP-1β were significantly lower in patients who required a high dose of morphine or who developed resistance to morphine treatment. In conclusion, this is the first report revealing that the plasma concentrations of several cytokines were significantly modulated during treatment and were correlated with treatment outcome of morphine. Our results suggest that plasma cytokine levels may be promising biomarkers for morphine treatment and that they warrant further study.

KW - Cytokines

KW - IL-12

KW - MIP-1α

KW - Morphine

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=84855170519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855170519&partnerID=8YFLogxK

M3 - Article

C2 - 22199331

AN - SCOPUS:84855170519

VL - 31

SP - 4561

EP - 4568

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -